Michael Osso News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves High-Concentration, Citrate-Free Cyltezo for the Treatment of Chronic Inflammatory Diseases

This citrate-free and high-dose approval of the biosimilar Humira provides another option to treat patients who are living with various inflammatory diseases.

United statesSteven taylorStephen pagnottaBiosimilar adalimumab adbmBoehringer ingelheimCrohn colitis foundationArthritis foundationMichael ossoColitis foundationHealthy peopleTest howBody when given

Bathroom Access Is a Public Health Issue

There are just eight public toilets per 100,000 people in the U.S.

United statesNew yorkTheodora teddy siegelNew york timesCrohns colitis foundationRestrooms movementCrohn colitis foundationFoundation we cant waitMount sinai icahn school of medicineMount sinaiIcahn schoolNew york cityMichael ossoJim crowColitis foundationOpen restrooms

Access to toilets is a public health issue - Independant Express

Access to toilets is a public health issue - Independant Express
independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkNew yorkerTheodora teddy siegelZoe gottliebIcahn school of medicine at mount sinaiToilet movementColitis foundationIcahn schoolMount sinaiNew york cityMichael ossoOpen toilet

FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis

Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.

Patrik jonssonBurrillb crohnEli lillyPbruce sandsHenryd janowitz division of gastroenterologyIcahn school of medicine at mount sinaiDrug administration issues complete response letterDrug administrationColitis foundationIcahn schoolBiologics license applicationComplete response letterUrgency numeric rating scaleMichael ossoLilly immunologyLilly united states

FDA Approves Mirikizumab for Moderately to Severely Active Ulcerative Colitis

Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.

United statesBurrillb crohnPbruce sandsPatrik jonssonEli lillyColitis foundationIcahn school of medicine at mount sinaiHenryd janowitz division of gastroenterologyIcahn schoolMount sinaiUrgency numeric rating scaleMichael ossoLilly immunologyLilly united states